Novo Nordisk sets $23B obesity sales target for 2030 as shares fall 7%
CEO Mike Doustdar told investors semaglutide's US patent exclusivity ends in 2032, a market that accounts for more than half of company sales.
TR
By Tom Reyes · Markets Editor
Sep 21 03:00 ETSource: TradingView
The wire
- 01At its Capital Markets Day in London, Novo Nordisk targeted $23B in obesity sales and more than five multi-blockbuster launches by 2030; shares slid as much as 7%.
- 02Novo says it plans to scale capacity to serve 10 times more people with obesity on oral GLP-1 by 2030, a signal on future supply for prescribers and pharmacies.
- 03Doustdar called loss of exclusivity the "elephant in the room"; Novo shares are down more than 70% from their peak while Lilly's have risen.
From the source
Read at tradingview.comNovo Nordisk shares slide 7% despite $23B obesity target, 2030 growth goals
Despite unveiling 2030 growth goals and a $23B obesity sales target, Novo Nordisk NVO saw its shares slide as much as 7% following its Capital Markets Day presentation in London on Monday.
